Volume | 0.00 |
|
|||||
News | - |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Brumby Res Fpo | BMY | Australian Stock Exchange | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
Trades | Shares Traded | Average Volume |
---|---|---|
0 | 0.00 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | AUD |
Brumby Resources News
Brumby Resources Discussion Forums - BMY
Date | Time | Comments | Title |
---|---|---|---|
8/01/2023 | 13:23 | - | AZN pays BMY/Ono Pharma $510M to_settle_all_patent_litigation_regarding Imjudo/I |
7/27/2023 | 11:37 | - | BMY 2Q23 CC transcript: |
7/27/2023 | 07:45 | - | BMY reports 2Q23 results—cuts 2023 non-GAAP EPS guidance: |
7/11/2023 | 07:30 | - | Opdivo monotherapy—>statsig OS/PFS as_addend_to_cisplatin_in first-line bladder cancer: |
7/10/2023 | 11:59 | - | BMY opts-in for worldwide rights_to PRTA’s anti-tau compound, PRX005: |
6/20/2023 | 08:23 | - | GERN submits Imetelstat NDA for treatment of transfusion-dependent |
6/17/2023 | 12:40 | - | BMY sues US government regarding IRA: |
6/06/2023 | 10:43 | - | BMY’s ASCO slide set: |
6/04/2023 | 14:04 | - | Opdivo bests Adcetris in first-line-HL PFS—immature_OS_data_trending_in_favor_of |
5/30/2023 | 05:51 | - | Repotrectinib NDA has 11/27/23 PDUFA date—(with FDA priority review): |
Historical BMY Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |